Both molecules are known to inhibit NADPH oxidase activity [55,56]; the overactivity of this enzyme complex plays a role in many physiological conditions, e.g., vascular disorders, neurodegenerative disorders, and hepatic fibrosis [57,58,59]. Here, FMO5 is linked to vascular disorder.